Literature DB >> 25134709

Parkinson disease: Can a new trial end controversy over when to use levodopa?

Olivier Rascol1.   

Abstract

Levodopa is the standard therapy for Parkinson disease, but prolonged use promotes the development of adverse motor effects. A new trial compared the effectiveness of levodopa administration early in the disease with therapies that used alternative dopaminergic agents before levodopa. No clinically relevant differences were found between the treatment strategies.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25134709     DOI： 10.1038/nrneurol.2014.147

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN： 1759-4758            Impact factor:   42.937


  9 in total

1.  Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients.

Authors:  Daniel Weintraub; Juergen Koester; Marc N Potenza; Andrew D Siderowf; Mark Stacy; Valerie Voon; Jacqueline Whetteckey; Glen R Wunderlich; Anthony E Lang
Journal:  Arch Neurol       Date:  2010-05

Review 2.  Parkinson's disease. First of two parts.

Authors:  A E Lang; A M Lozano
Journal:  N Engl J Med       Date:  1998-10-08       Impact factor: 91.245

3.  Effect of deprenyl on the progression of disability in early Parkinson's disease.

Authors: 
Journal:  N Engl J Med       Date:  1989-11-16       Impact factor: 91.245

4.  Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson's disease.

Authors:  Rajesh Pahwa; Kelly E Lyons; Robert A Hauser; Stanley Fahn; Joseph Jankovic; Emmanuelle Pourcher; Ann Hsu; Martin O'Connell; Sherron Kell; Suneel Gupta
Journal:  Parkinsonism Relat Disord       Date:  2013-09-05       Impact factor: 4.891

Review 5.  Limitations of current Parkinson's disease therapy.

Authors:  Olivier Rascol; Pierre Payoux; Fabienne Ory; Joaquim J Ferreira; Christine Brefel-Courbon; Jean-Louis Montastruc
Journal:  Ann Neurol       Date:  2003       Impact factor: 10.422

6.  Long-term treatment of Parkinson's disease with bromocriptine.

Authors:  A Rascol; B Guiraud; J L Montastruc; J David; M Clanet
Journal:  J Neurol Neurosurg Psychiatry       Date:  1979-02       Impact factor: 10.154

7.  Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease.

Authors:  C Warren Olanow; Karl Kieburtz; Olivier Rascol; Werner Poewe; Anthony H Schapira; Murat Emre; Helena Nissinen; Mika Leinonen; Fabrizio Stocchi
Journal:  Mov Disord       Date:  2013-04-29       Impact factor: 10.338

8.  Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial.

Authors:  Fabienne Ory-Magne; Jean-Christophe Corvol; Jean-Philippe Azulay; Anne-Marie Bonnet; Christine Brefel-Courbon; Philippe Damier; Estelle Dellapina; Alain Destée; Franck Durif; Monique Galitzky; Thibaud Lebouvier; Wassilios Meissner; Claire Thalamas; François Tison; Alexandrine Salis; Agnès Sommet; François Viallet; Marie Vidailhet; Olivier Rascol
Journal:  Neurology       Date:  2013-12-26       Impact factor: 9.910

9.  Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial.

Authors:  Richard Gray; Natalie Ives; Caroline Rick; Smitaa Patel; Alastair Gray; Crispin Jenkinson; Emma McIntosh; Keith Wheatley; Adrian Williams; Carl E Clarke
Journal:  Lancet       Date:  2014-06-11       Impact factor: 79.321
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.